Literature DB >> 21737265

Discovery and synthesis of a new class of opioid ligand having a 3-azabicyclo[3.1.0]hexane core. An example of a 'magic methyl' giving a 35-fold improvement in binding.

Graham Lunn1, Bernard J Banks, Robert Crook, Neil Feeder, Alan Pettman, Yogesh Sabnis.   

Abstract

In looking for a novel achiral μ opioid receptor antagonist for the treatment of pruritus, we designed and synthesised azabicyclo[3.1.0]hexane compounds as a new class of opioid ligand. During optimisation, an addition of a single methyl resulted in a 35-fold improvement in binding. An early example from the series had excellent μ opioid receptor antagonist antagonist activity and was very effective in an in vivo pruritus study.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21737265     DOI: 10.1016/j.bmcl.2011.05.132

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  3 in total

1.  Synthesis of bis-spirocyclic derivatives of 3-azabicyclo[3.1.0]hexane via cyclopropene cycloadditions to the stable azomethine ylide derived from Ruhemann's purple.

Authors:  Alexander S Filatov; Olesya V Khoroshilova; Anna G Larina; Vitali M Boitsov; Alexander V Stepakov
Journal:  Beilstein J Org Chem       Date:  2022-06-29       Impact factor: 2.544

2.  Multienzyme One-Pot Cascades Incorporating Methyltransferases for the Strategic Diversification of Tetrahydroisoquinoline Alkaloids.

Authors:  Fabiana Subrizi; Yu Wang; Benjamin Thair; Daniel Méndez-Sánchez; Rebecca Roddan; Max Cárdenas-Fernández; Jutta Siegrist; Michael Richter; Jennifer N Andexer; John M Ward; Helen C Hailes
Journal:  Angew Chem Int Ed Engl       Date:  2021-07-16       Impact factor: 16.823

3.  Synthesis of CHF2-substituted 3-azabicyclo[3.1.0]hexanes by photochemical decomposition of CHF2-pyrazolines.

Authors:  Yang Zheng; Xinling Yu; Songyang Lv; Pavel K Mykhailiuk; Qiang Ma; Li Hai; Yong Wu
Journal:  RSC Adv       Date:  2018-01-29       Impact factor: 4.036

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.